Quest Diagnostics (DGX) News
Market Cap: $19.90B
Avg Volume: 1.32M
Industry: Medical - Diagnostics & Research
Sector: Healthcare
These Analysts Boost Their Forecasts On Quest Diagnostics After Better-Than-Expected Q1 Earnings
Quest Diagnostics Incorporated DGX posted better-than-expected first-quarter earnings on Tuesday.
benzinga.com
Read More
Quest Diagnostics Revenue Rebound, Strategic Moves Fuel Outlook Confidence
Quest Diagnostics Inc DGX reported on Tuesday that first-quarter 2025 sales of $2.65 billion, up 12.1% year over year, beat the consensus of $2.63 billion.
benzinga.com
Read More
Quest Diagnostics Incorporated (DGX) Q1 2025 Earnings Call Transcript
Quest Diagnostics Incorporated (NYSE:DGX ) Q1 2025 Results Conference Call April 22, 2025 8:30 AM ET Company Participants Shawn Bevec - Vice President of Investor Relations Jim Davis - Chairman, Chief Executive Officer, President Sam Samad - Chief Financial Officer Conference Call Participants Luke Sergott - Barclays Kevin Caliendo - UBS Patrick Donnelly - Citi Elizabeth Anderson - Evercore ISI Michael Cherny - Leerink Partners Pito Chickering - Deutsche Bank Noah Kava - Jefferies David Westenberg - Piper Sandler Michael Ryskin - Bank of America Andrew Brackmann - William Blair Jack Meehan - Nephron Research Erin Wright - Morgan Stanley Operator Welcome to the Quest Diagnostics First Quarter 2025 Conference Call. At the request of the company, this call is being recorded.
seekingalpha.com
Read More
Quest Diagnostics Q1 Earnings & Revenues Top Estimates, Stock Up
DGX delivers solid top-line growth in the first quarter of 2025.
zacks.com
Read More
Quest Diagnostics (DGX) Q1 Earnings and Revenues Beat Estimates
Quest Diagnostics (DGX) came out with quarterly earnings of $2.21 per share, beating the Zacks Consensus Estimate of $2.15 per share. This compares to earnings of $2.04 per share a year ago.
zacks.com
Read More
Quest beats quarterly profit estimates on strong demand for diagnostic tests
Laboratory operator Quest Diagnostics beat Wall Street estimates for first-quarter profit on Tuesday, helped by robust demand for its diagnostic tests.
reuters.com
Read More
Quest Diagnostics earnings beat after March rebound in demand from slump early in the quarter
Quest Diagnostics Inc.'s stock fell 3.6% early Tuesday, after the company posted better-than-expected first-quarter earnings and backed its guidance, but said the early part of the quarter was slow.
marketwatch.com
Read More
Quest Diagnostics Reports First Quarter 2025 Financial Results; Reaffirms Revenue and Adjusted Diluted EPS Guidance for Full Year 2025
First quarter revenues of $2.65 billion, up 12.1% from 2024 First quarter reported diluted earnings per share ("EPS") of $1.94, up 12.8% from 2024; and adjusted diluted EPS of $2.21, up 8.3% from 2024 Full year 2025 reported diluted EPS now expected to be between $8.62 and $8.87; and adjusted diluted EPS is expected to remain between $9.55 and $9.80 SECAUCUS, N.J. , April 22, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the first quarter ended March 31, 2025.
prnewswire.com
Read More
Quest Diagnostics (DGX) Earnings Expected to Grow: Should You Buy?
Quest Diagnostics (DGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
zacks.com
Read More
Here's How Quest Diagnostics is Placed Ahead of Q1 Earnings
DGX's first-quarter 2025 performance is likely to have been supported by the ongoing utilization of its Advanced Diagnostics and benefits from acquisitions.
zacks.com
Read More
DGX Stock Gains Following the Launch of New AD-Detect Blood Test
Quest Diagnostics introduces AD-Detect Abeta, a new laboratory blood test, to detect Alzheimer's disease without any PET imaging and cerebral spinal fluid testing.
zacks.com
Read More
Quest Diagnostics Launches New AD-Detect™ Blood Test to Aid in Confirming Alzheimer's Disease
In an oral presentation at the 2025 AAN Annual Meeting, Quest scientists presented data suggesting the test can accurately assess Alzheimer's disease pathology with greater than 90% sensitivity and specificity SECAUCUS, N.J. , April 9, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, including advanced diagnostics for brain health, today announced the launch of a new laboratory blood test designed to help physicians confirm amyloid brain pathology due to Alzheimer's disease (AD) in patients with mild cognitive impairment (MCI) or dementia.
prnewswire.com
Read More
T-Mobile Leads Five Stocks To Watch As Market Correction Intensifies
This weekend's stocks to watch are defensive plays. They boast strong relative strength, but still suffered losses amid the market sell-off.
investors.com
Read More
8 Upcoming Dividend Increases During Volatile Times
8 Upcoming Dividend Increases During Volatile Times
seekingalpha.com
Read More
Quest Diagnostics Introduces HPV Specimen Self-Collection for Cervical Cancer Screening
Providers in the United States may now order the FDA-cleared HPV self-collection solution for their patients to use in their offices or other healthcare settings, with goal to reduce barriers to screening by enabling discreet self-collection Quest also plans to make self-collection option available at its 2,000 patient service centers in the United States early next month, expanding access to screening New solution follows company's launch of GTI self-collection option for several STIs and related conditions last fall SECAUCUS, N.J. , April 2, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced a new solution aimed at broadening access to human papillomavirus (HPV) screening to help identify women who are at risk of developing cervical cancer.
prnewswire.com
Read More
Quest Diagnostics to Release First Quarter 2025 Financial Results on April 22, 2025
SECAUCUS, N.J. , April 1, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that it will report first quarter 2025 financial results on Tuesday, April 22, 2025, before the market opens.
prnewswire.com
Read More
Is Quest Diagnostics Stock Worth Holding Onto Right Now?
Strong momentum in Advanced Diagnostics and strategic acquisitions continues to attract investors to DGX.
zacks.com
Read More
DGX Stock Set to Benefit From New Google Cloud Partnership
Quest Diagnostics teams up with Google Cloud to streamline data and personalize customer experiences using gen AI.
zacks.com
Read More
Tap Billion-Dollar AI Opportunity in Oncology: Stocks in the Spotlight
Betting on AI-driven precision oncology companies presents a compelling long-term opportunity for investors. Some of the stocks in focus are BTAI, TEM and DGX.
zacks.com
Read More
Quest Diagnostics to Highlight Strategic Priorities to Drive Sustainable Growth and Deliver Long-term Shareholder Value at 2025 Investor Day
Provides long-term outlook beyond 2025: Revenues expected to grow at 4-5% compound annual growth rate (CAGR); adjusted diluted earnings per share (EPS) expected to grow at 7-9% CAGR Reaffirms guidance for full year 2025 SECAUCUS, N.J. , March 19, 2025 /PRNewswire/ -- At a meeting with analysts and investors at its 2025 Investor Day, members of the leadership team of Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, will discuss the company's strategies to drive sustainable growth and deliver long-term shareholder value.
prnewswire.com
Read More
Quest Diagnostics to Collaborate with Google Cloud to Streamline Data and Personalize Customer Experiences Using Generative AI
SUNNYVALE, Calif. and SECAUCUS, N.J.
prnewswire.com
Read More
Quest Diagnostics Stock Jumps 38% in a Year: What's Behind the Surge?
DGX outperforms the industry and the S&P 500 composite's gain in the past year, driven by strong core performance and contributions from acquisitions.
zacks.com
Read More
Is it Apt to Hold Quest Diagnostics Stock in Your Portfolio Now?
DGX stays on investors' radars due to its robust prospects in Advanced Diagnostics and progress in the acquisition strategy.
zacks.com
Read More
Fresenius Medical Care Announces Divestment of Select Laboratory Assets to Quest Diagnostics
Quest to provide comprehensive dialysis-related laboratory and water testing services to Fresenius Medical Care owned and affiliated clinics in the United States BAD HOMBURG, Germany and SECAUCUS, N.J. , Feb. 24, 2025 /PRNewswire/ -- Fresenius Medical Care (XETRA: FME; NYSE: FMS), the world's leading provider of products and services for individuals with renal disease, and Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that, under terms of a definitive acquisition agreement, Quest will acquire select assets of FME's wholly owned Spectra Laboratories, a leading provider of renal-specific laboratory testing services in the U.S. In addition, under a separate agreement, Quest will provide comprehensive laboratory services related to end-stage kidney disease (ESKD) and specialized water testing for patients and providers served by dialysis centers operated by Fresenius Medical Care and its wholly owned and joint-venture partners in the United States.
prnewswire.com
Read More
Quest Diagnostics to Host Investor Day on March 19, 2025
SECAUCUS, N.J. , Feb. 13, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, will host an Investor Day for institutional investors and financial analysts in New York City on Thursday, March 19, 2025 at the New York Stock Exchange.
prnewswire.com
Read More
GRAIL and Quest Diagnostics Provide GRAIL's Galleri® Multi-Cancer Early Detection (MCED) Test Through the Quest Diagnostics Test Ordering System
GRAIL's Galleri Test Now Directly Available to Physicians in the U.S. Through Collaboration With Quest Diagnostics, Delivering a More Streamlined Provider and Patient Experience MENLO PARK, Calif. and SECAUCUS, N.J.
prnewswire.com
Read More
Why Quest Diagnostics (DGX) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
zacks.com
Read More
Quest Diagnostics Stock to Gain From Innovation Amid Industry Threats
Within brain health, the robust demand for AD-detect blood tests for assessing Alzheimer's disease risk drives solid growth for DGX in the fourth quarter of 2024.
zacks.com
Read More
Why Quest Diagnostics (DGX) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
zacks.com
Read More
Here's Why Quest Diagnostics (DGX) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
zacks.com
Read More
Quest Diagnostics (DGX) is a Great Momentum Stock: Should You Buy?
Does Quest Diagnostics (DGX) have what it takes to be a top stock pick for momentum investors? Let's find out.
zacks.com
Read More
Quest Diagnostics Named to Fortune's World's Most Admired Companies List for 11th Consecutive Year
SECAUCUS, N.J. , Jan. 30, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that it has been selected as one of the 2025 World's Most Admired Companies™ by Fortune® magazine, the 11th consecutive year the company has been named to the elite list of globally respected companies.
prnewswire.com
Read More
Why Quest Diagnostics Stock Was Blasting Higher Today
Quest Diagnostics (DGX 5.49%) stock was teasing its all-time high on Thursday, no mean feat for a company that's been publicly traded for decades. The healthcare testing specialist's share price was up by more than 5% in late afternoon action, well ahead of the S&P 500 index's 0.8% gain at that point in the day.
fool.com
Read More
Quest Diagnostics Incorporated (DGX) Q4 2024 Earnings Call Transcript
Quest Diagnostics Incorporated (NYSE:DGX ) Q4 2024 Earnings Conference Call January 30, 2025 8:30 AM ET Company Participants Jim Davis - President & CEO Sam Samad - EVP & CFO Shawn Bevec - VP, IR Conference Call Participants Kevin Caliendo - UBS Patrick Donnelley - Citi Michael Cherny - Leerink Partners Joanna Zhou - Evercore ISI Pito Chickering - Deutsche Bank David Westenberg - Piper Sandler Andrew Brackmann - William Blair Noah Kava - Jefferies Jack Meehan - Nephron Research Erin Wright - Morgan Stanley Operator Welcome to the Quest Diagnostics Fourth Quarter and Full-Year 2024 Conference Call. At the request of the company, this call is being recorded.
seekingalpha.com
Read More
Quest Diagnostics EPS Tops Predictions
Quest Diagnostics (DGX 6.36%), a leader in diagnostic testing and information services, released its fourth quarter results on Jan. 30. The company reported a notable quarter with adjusted earnings per share (EPS) of $2.23, surpassing the analyst projection of $2.18.
fool.com
Read More
DGX Stock Dips Despite Q4 Earnings and Revenue Beat, Margins Rise
Quest Diagnostics' fourth-quarter 2024 performance benefits from the strength of its core business.
zacks.com
Read More
Quest Diagnostics (DGX) Q4 Earnings and Revenues Top Estimates
Quest Diagnostics (DGX) came out with quarterly earnings of $2.23 per share, beating the Zacks Consensus Estimate of $2.19 per share. This compares to earnings of $2.15 per share a year ago.
zacks.com
Read More
Quest Diagnostics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Guidance for Full Year 2025; Increases Quarterly Dividend 6.7% to $0.80 Per Share
Fourth quarter revenues of $2.62 billion, up 14.5% from 2023 Fourth quarter reported diluted earnings per share ("EPS") of $1.95, up 14.7% from 2023; and adjusted diluted EPS of $2.23, up 3.7% from 2023 Full year revenues of $9.87 billion, up 6.7% from 2023 Full year reported diluted EPS of $7.69, up 2.7% from 2023; and adjusted diluted EPS of $8.93, up 2.5% from 2023 Full year 2025 reported diluted EPS expected to be between $8.34 and $8.59; and adjusted diluted EPS expected to be between $9.55 and $9.80 SECAUCUS, N.J. , Jan. 30, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, announced today financial results for the fourth quarter and full year ended December 31, 2024.
prnewswire.com
Read More
Quest Diagnostics Completes Acquisition of the Outreach Lab Services Business of University Hospitals
Physicians and patients to benefit from access to Quest's industry-leading test menu and broad health plan relationships in Ohio SECAUCUS, N.J. and CLEVELAND , Jan. 27, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced it has completed its previously announced acquisition of select assets of University Hospitals, one of the nation's leading nonprofit health systems and academic medical centers.
prnewswire.com
Read More
Should Value Investors Buy Quest Diagnostics (DGX) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
zacks.com
Read More
Quest Diagnostics Q4 Earnings Preview: What's in Store for the Stock?
Quest Diagnostics is likely to have driven strong performances in the key physician and hospital channels in the fourth quarter of 2024.
zacks.com
Read More
Zacks Industry Outlook Quest Diagnostics, DaVita, Option Care Health and Addus HomeCare
Quest Diagnostics, DaVita, Option Care Health and Addus HomeCare have been highlighted in this Industry Outlook article.
zacks.com
Read More
4 Stocks to Monitor in a Dynamic Outpatient Home Health Industry
An aging global population and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry despite the macroeconomic challenges. DGX, DVA, OPCH and ADUS are well-poised to gain.
zacks.com
Read More
Quest Diagnostics Names Adrienne Brott Senior Vice President and Chief Quality and Regulatory Affairs Officer
Quality and regulatory veteran of Getinge, BD and J&J joins the Quest Diagnostics executive team SECAUCUS, N.J. , Jan. 8, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that Adrienne L.
prnewswire.com
Read More
Why Quest Diagnostics (DGX) is Poised to Beat Earnings Estimates Again
Quest Diagnostics (DGX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
zacks.com
Read More
Quest Diagnostics to Release Fourth Quarter and Full Year 2024 Financial Results on January 30, 2025
SECAUCUS, N.J. , Jan. 2, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that it will report fourth quarter and full year 2024 financial results on Thursday, January 30, 2025, before the market opens.
prnewswire.com
Read More
Should You Hold Quest Diagnostics Stock in Your Portfolio Now?
DGX's strength in the base business and the robust adoption of Advanced Diagnostics services bode well.
zacks.com
Read More
New Health Coaching Service on questhealth.com Set to Boost DGX Stock
Quest Diagnostics introduces Health Coaching on questhealth.com, helping individuals take control of their health.
zacks.com
Read More
Quest Diagnostics to Speak at the 7th Annual Evercore HealthCONx Conference
SECAUCUS, N.J. , Dec. 3, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak on the company's strategy, performance and the latest market developments and trends during a fireside chat at the 7th Annual Evercore HealthCONx Conference in Miami on Wednesday, December 4, 2024, at 3:00 p.m.
prnewswire.com
Read More
Quest Diagnostics Launches Health Coaching on questhealth.com to Help Individuals Take Control of Their Health
New service takes the guesswork out of achieving one's health goals by empowering individuals to pair Quest lab results with personalized coaching SECAUCUS, N.J,, Dec. 3, 2024 /PRNewswire/ -- Personalized, one-on-one health coaching is now available for purchase on questhealth.com. Made available by Pack Health® , a Quest Diagnostics (NYSE: DGX) company that provides evidence-based patient engagement services, questhealth.com's Health Coaching pairs individuals with board-certified health advisers who provide personalized support, resources, and education focused on the individual's unique health goals.
prnewswire.com
Read More
Quest Diagnostics (DGX) Up 2.7% Since Last Earnings Report: Can It Continue?
Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock?
zacks.com
Read More
Augurex Life Sciences and Quest Diagnostics Collaborate to Improve Rheumatoid Arthritis Diagnosis and Management
VANCOUVER, British Columbia--(BUSINESS WIRE)-- #AxialSpondyloarthritis--Augurex Life Sciences Corp., a leader in autoimmune biomarker-based diagnostics, today announced that it has formed a nonexclusive agreement with Quest Diagnostics, a leading provider of diagnostic information services, under which Quest will validate and offer a lab-developed test based on the Augurex 14-3-3η (eta) biomarker in the United States. Quest intends to begin offering the test service to physicians from its advanced laboratory in San Juan.
businesswire.com
Read More
All You Need to Know About Quest Diagnostics (DGX) Rating Upgrade to Buy
Quest Diagnostics (DGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
zacks.com
Read More
Is Quest Diagnostics Stock a Smart Addition to Your Portfolio Now?
DGX exhibits strength in its base business. Increasing utilization of the Advanced Diagnostics offering is another positive.
zacks.com
Read More
Quest Diagnostics Declares Quarterly Cash Dividend
SECAUCUS, N.J. , Nov. 12, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.75 per share, payable on January 29, 2025 to shareholders of record of Quest Diagnostics common stock on January 14, 2025.
prnewswire.com
Read More
DGX vs. PNTG: Which Stock Is the Better Value Option?
Investors interested in Medical - Outpatient and Home Healthcare stocks are likely familiar with Quest Diagnostics (DGX) and The Pennant Group, Inc. (PNTG). But which of these two companies is the best option for those looking for undervalued stocks?
zacks.com
Read More
Here's Why You Should Retain DGX Stock in Your Portfolio Now
Investors feel optimistic about Quest Diagnostics' strength in Advanced Diagnostics. Robust base business volumes are also encouraging.
zacks.com
Read More
Quest Diagnostics Incorporated (DGX) Soars to 52-Week High, Time to Cash Out?
Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
zacks.com
Read More
Quest Diagnostics Has Massive Secular Tailwinds And A Strong Base
Quest Diagnostics benefits from an aging population, driving increased lab testing volumes, particularly in genetic testing, and offers a 2.0% dividend yield. DGX's M&A strategy, including the LifeLabs acquisition, aims to expand its footprint and diversify operations, despite short-term EPS dilution. The company faces risks from PAMA reimbursement cuts and labor market challenges but expects long-term growth from organic and acquisition activities.
seekingalpha.com
Read More
Quest Diagnostics: Organic Growth Leads To Q3 Earnings Beat
Quest Diagnostics reported strong Q3 earnings, with an 8.5% revenue increase and a 3.6% rise in diluted EPS, beating Street expectations. The company raised its 2024 revenue guidance and expects significant growth from recent and upcoming acquisitions, projecting double-digit revenue growth for Q4. Despite risks like economic downturns and inflation, I maintain a bullish outlook on DGX, adjusting my Buy Threshold to $150 and Sell Target to $227.
seekingalpha.com
Read More
DGX or PNTG: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Outpatient and Home Healthcare sector might want to consider either Quest Diagnostics (DGX) or The Pennant Group, Inc. (PNTG). But which of these two companies is the best option for those looking for undervalued stocks?
zacks.com
Read More
4 Stocks to Buy in an Evolving Outpatient Home Health Industry
Dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry despite the macroeconomic challenges. DGX, EHC, AMED and ADUS are well-poised to gain.
zacks.com
Read More
US lab operator Quest Diagnostics to launch bird flu test at end of October
Lab operator Quest Diagnostics said on Wednesday it will launch a test for H5N1 bird flu at the end of October after the U.S. Centers for Disease Control and Prevention (CDC) gave it contracts to support testing for two emerging infectious diseases, including the Oropouche virus.
reuters.com
Read More
Quest Diagnostics Awarded CDC Contracts for H5 Avian Influenza and Oropouche Virus Test Development
Quest to develop laboratory tests and support public health reporting and laboratory readiness for CDC's preparedness strategy; Company to introduce clinical testing for avian flu later this month based on one of the awards SECAUCUS, N.J. , Oct. 23, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that it has been awarded several contracts by the U.S. Centers for Disease Control and Prevention (CDC) to support testing and sustained laboratory readiness for two emerging infectious diseases recently identified in people in the Americas.
prnewswire.com
Read More
Overlooked Stock: DGX
One of the biggest earnings movers from Tuesday: Quest Diagnostics (DGX). The lab & testing company beat on the top-and-bottom line in its 3Q report, as shares surged to multi-month highs.
youtube.com
Read More
Quest Diagnostics (DGX) Q3 2024 Earnings Call Transcript
Quest Diagnostics Incorporated (NYSE:DGX ) Q3 2024 Earnings Conference Call October 22, 2023 8:30 AM ET Company Participants Jim Davis - President, Chief Executive Officer Sam Samad - Executive Vice President, Chief Financial Officer Shawn Bevec - Vice President, Investor Relations Conference Call Participants Ann Hynes - Mizuho Securities Michael Cherny - Leerink Partners Patrick Donnelly - Citi Pito Chickering - Deutsche Bank Meghan Holtz - Jefferies David Westenberg - Piper Sandler Jack Meehan - Nephron Research Elizabeth Anderson - Evercore ISI Erin Wright - Morgan Stanley Stephanie Davis - Barclays Lisa Gill - JP Morgan Andrew Brackmann - William Blair Kevin Caliendo - UBS Michael Riskin - Bank of America Operator Welcome to the Quest Diagnostics Third Quarter 2024 conference call. At the request of the company, this call is being recorded.
seekingalpha.com
Read More
Quest Diagnostics CEO Touts 'New Customer Wins' In Q3, Expects Earnings Growth In 2025
Quest Diagnostics Inc DGX posted third-quarter adjusted earnings per share of $2.30, beating the consensus of $2.26.
benzinga.com
Read More
DGX Stock Rises on Q3 Earnings and Revenue Beat, 2024 Sales View Up
Quest Diagnostics' third-quarter 2024 performance reflects impressive DIS business growth and the benefits of new acquisitions.
zacks.com
Read More
Quest Diagnostics (DGX) Beats Q3 Earnings and Revenue Estimates
Quest Diagnostics (DGX) came out with quarterly earnings of $2.30 per share, beating the Zacks Consensus Estimate of $2.26 per share. This compares to earnings of $2.22 per share a year ago.
zacks.com
Read More
Quest Diagnostics beats quarterly results estimates on diagnostic test demand
Laboratory operator Quest Diagnostics beat Wall Street estimates for third-quarter profit and revenue on Tuesday, helped by robust demand for its diagnostic tests.
reuters.com
Read More
Quest Diagnostics Reports Third Quarter 2024 Financial Results; Updates Guidance for Full Year 2024
Third quarter revenues of $2.49 billion, up 8.5% from 2023 Third quarter reported diluted earnings per share ("EPS") of $1.99, up 1.5% from 2023; and adjusted diluted EPS of $2.30, up 3.6% from 2023 Full year 2024 revenues now expected to be between $9.80 billion and $9.85 billion; reported diluted EPS now expected to be between $7.60 and $7.70; and adjusted diluted EPS expected to be between $8.85 and $8.95 SECAUCUS, N.J. , Oct. 22, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the third quarter ended September 30, 2024.
prnewswire.com
Read More
Are Investors Undervaluing Quest Diagnostics (DGX) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
zacks.com
Read More
Quest Diagnostics (DGX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Quest Diagnostics (DGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
zacks.com
Read More
Quest Diagnostics Introduces Specimen Self-Collection for Common Genital Tract Infection Testing at Nationwide Network of Patient Service Centers
First-of-its-kind service empowers discreet and more convenient access to testing and treatment for vaginitis and similar genital tract infections such as chlamydia, gonorrhea, trichomoniasis and Mycoplasma genitalium Self-collection option available at no extra charge at any of Quest's 2,000 patient service centers with a physician's order or through Quest's consumer-initiated test platform at questhealth.com SECAUCUS, N.J. , Oct. 15, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced the availability of a new service aimed at increasing convenience and speed of testing and treatment of several common genital tract infections (GTIs).
prnewswire.com
Read More
Quest Diagnostics: The Better Half Of An Emerging Healthcare Duopoly
Quest Diagnostics is a dominant player in the growing medical testing industry, offering consistent earnings and dividend growth with lower volatility. DGX benefits from secular tailwinds like aging populations and preventive medical testing, promising 10% annual returns and 6-8% annual dividend growth. DGX's financials have stabilized post-Covid, with revenue, earnings, and free cash flow rising, supported by share buybacks and strategic acquisitions.
seekingalpha.com
Read More
DGX Gears Up for Q3 Earnings: What Lies Ahead for the Stock?
Quest Diagnostics is expected to deliver robust base business growth in the third quarter of 2024.
zacks.com
Read More
Quest Diagnostics Completes Acquisition of Lab Assets from OhioHealth
Goal to broaden access to cost-effective and innovative laboratory services in Ohio SECAUCUS, N.J. , Oct. 14, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that it has completed its previously announced acquisition of select laboratory assets from OhioHealth, a nationally recognized not-for-profit, charitable, integrated health system.
prnewswire.com
Read More
Should You Add Quest Diagnostics Stock to Your Portfolio Right Now?
DGX's strength in Advanced Diagnostics and robust base business volumes are encouraging.
zacks.com
Read More
Is Quest Diagnostics (DGX) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
zacks.com
Read More
Quest Diagnostics to Release Third Quarter 2024 Financial Results on October 22, 2024
SECAUCUS, N.J. , Sept. 25, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that it will report third quarter 2024 financial results on Tuesday, October 22, 2024, before the market opens.
prnewswire.com
Read More
Quest Diagnostics Stock Gains From New Offerings, Customer Wins
A key driver in Brain Health growth is Quest Diagnostics' Alzheimer's disease portfolio, featuring the AD-Detect blood testing services and the CSF tests.
zacks.com
Read More
Here's Why Quest Diagnostics (DGX) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
zacks.com
Read More
DGX Stock to Benefit From New Partnership With Sentara Health Plans
Quest Diagnostics extends services in Virginia and Florida via a partnership with Sentara Health Plans.
zacks.com
Read More
Sentara Health Plans and Quest Diagnostics Form Strategic Collaboration to Extend Lab Access in Parts of the Southeast
Quest named exclusive independent lab provider for all Sentara Health Plans in Virginia and Florida SECAUCUS, N.J and HAMPTON ROADS, Va. , Sept. 18, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and Sentara Health Plans, the health plan division of Sentara Health, an integrated, not-for-profit health care delivery system, today announced a multi-year strategic collaboration designed to expand access to high-quality, affordable and comprehensive laboratory testing for members of Sentara Health Plans.
prnewswire.com
Read More
DGX Stock Likely to Gain From Allina Health's Select Lab Assets Buyout
With the completion of the acquisition, Allina Health's clinic physicians will now have access to Quest Diagnostics' laboratory services.
zacks.com
Read More
Quest Diagnostics Completes Acquisition of Select Lab Assets from Allina Health
SECAUCUS, N.J. , Sept. 16, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that it has completed its previously announced acquisition of select laboratory assets from Allina Health.
prnewswire.com
Read More
Quest Diagnostics to Speak at the Morgan Stanley 22nd Annual Global Healthcare Conference
SECAUCUS, N.J. , Aug. 28, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak on the company's strategy, performance and the latest market developments and trends during a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference in New York City on Friday, September 6, 2024, at 10:45 a.m.
prnewswire.com
Read More
Quest Diagnostics Expands in North America With New Acquisition
DGX acquires 100% of LifeLabs from OMERS, at approximately $1 billion. It will help LifeLabs to improve healthcare for Canadians.
zacks.com
Read More
Quest Diagnostics' (DGX) New Deal Aids Diagnostic Access in Ohio
Quest Diagnostics (DGX) signs an agreement to acquire select assets of University Hospitals' outreach laboratory services business.
zacks.com
Read More
Quest Diagnostics Completes Acquisition of LifeLabs, Enhancing Access to Diagnostic Innovation
SECAUCUS, N.J. and TORONTO , Aug. 26, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced the completion of its acquisition of LifeLabs from OMERS.
prnewswire.com
Read More
Quest Diagnostics (DGX) Up 6.3% Since Last Earnings Report: Can It Continue?
Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock?
zacks.com
Read More
Quest Diagnostics Incorporated (DGX) Hits Fresh High: Is There Still Room to Run?
Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
zacks.com
Read More
Quest Diagnostics to Acquire University Hospitals' Outreach Laboratory Services Business
Transaction to broaden access to innovative, quality diagnostic information services powering affordable care in Ohio SECAUCUS, N.J., and CLEVELAND , Aug. 21, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, and University Hospitals, one of the nation's leading nonprofit health systems and academic medical centers, today announced a definitive agreement for Quest to acquire select assets of University Hospitals' outreach laboratory services business.
prnewswire.com
Read More
Quest Diagnostics (DGX) Debuts Micronutrient Deficiency Panels
Quest Diagnostics (DGX) introduces 13 blood tests to identify micronutrient deficiencies.
zacks.com
Read More
Quest Diagnostics Prices $1.85 Billion of Senior Notes
SECAUCUS, N.J. , Aug. 15, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX) (the "Company"), a leader in diagnostic information services, today announced the pricing of a public offering of $400 million aggregate principal amount of its 4.600% senior notes due 2027 (the "2027 notes"), $600 million aggregate principal amount of its 4.625% senior notes due 2029 (the "2029 notes") and $850 million aggregate principal amount of its 5.000% senior notes due 2034 (the "2034 notes," and together with the 2027 notes and the 2029 notes, the "notes") under Quest Diagnostics' shelf registration statement.
prnewswire.com
Read More
Quest Diagnostics' (DGX) New Study Exposes Alarming Data on STI
Quest Diagnostics' (DGX) joint study with the University of Alabama finds pregnant women undertested for STIs, raising serious concerns on maternal and newborn health.
zacks.com
Read More
questhealth.com Introduces 13 New Blood Tests to Identify Micronutrient Deficiencies
Lab tests offer insights for individuals who may experience inadequate intake of essential nutrients due to dietary restrictions, certain prescription medications, or chronic health conditions SECAUCUS, N.J. , Aug. 15, 2024 /PRNewswire/ -- Micronutrients are essential vitamins and minerals that are vital for well-being and disease prevention, but deficiencies can commonly be caused by food allergies and dietary restrictions, certain prescription medications, or chronic health conditions.
prnewswire.com
Read More